Sanofi Says Pfizer’s PCSK9 Phase III Plan Will Boost The New Drug Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi CEO Christopher Viehbacher seemed unperturbed by Pfizer’s ambitious PCSK9 Phase III development program, saying it will increase interest in the new drug class.
You may also be interested in...
Sanofi Channel Stuffing In Brazil?
Sanofi CEO Chris Viehbacher showed clear signs of disappointment during the company’s earnings call, admitting emerging markets underperformed, and revealing a debacle in Brazil that appears to be channel stuffing.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.